Trastuzumab deruxtecan was approved for the treatment of locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who had received a prior trastuzumab-based regimen on 15 January 2021 [92]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.